Sanofi: holds over 95% of Kiadis' capital at end of offer

(CercleFinance.com) - At the end of its 308 million euro bid for the Dutch immunotherapy specialist, Sanofi controlled just over 95% of Kiadis' capital, it announced on Tuesday.


After the bid closed yesterday, about 39.9 million shares had been tendered, equivalent to 92.9% of the capital of the specialist in cell-based treatments for infectious diseases.

Taking into account the shares already held directly and indirectly by Sanofi, it now owns 95.03%, a figure that exceeds the threshold for acceptance of the offer, set at 80%.

The offer, which is now declared unconditional, will be reopened from tomorrow until 28 April.


Copyright (c) 2021 CercleFinance.com. All rights reserved.